Authors retain all rights in any data supplements associated with their articles The ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of ...

Under Dr. Manabe’s leadership, Daiichi Sankyo’s pioneering science and technology led to the resurgence of antibody drug conjugate (ADC) development within the pharmaceutical industry ...

A diverse range of social media tactics were used by pharma and biotech companies at ASCO this year. "HCPs: Visit booth 19045 at #ASCO13 to learn about BI's robust and growing #oncology #pipeline ...

Under Dr Manabe’s leadership, Daiichi Sankyo’s pioneering science and technology led to the resurgence of antibody drug conjugate (ADC) development within the pharmaceutical industry, leading to three ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

If pharma wants to help the NHS improve outcomes, it needs to do so through a true partnership rather than a transactional relationship. That’s according to Daiichi Sankyo’s UK managing ...

Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...

(RTTNews) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive Officer, succeeding Sunao Manabe, with effect from ...